Possible Benefit of GR43175, A Novel 5-HT1-Like Receptor Agonist for the Acute Treatment of Severe Migraine
Lancet 1:1309-1311, Doenicke,A.,et al, 1988
Dopamine Agonists, In Parkinson's Disease and Movement Disorders
Urban & Schwarzenberg, Balt, p. 104., Jankovic,J.&Tolosa,E., 1988
Improvement of Hepatic Encephalopathy Treated with Flumazenil
Lancet 2:1392-1394, Grimm,G.,et al, 1988
Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988
PHNO[ (+) -4-Propyl-9-Hydroxynaphthoxazine]:A New and Effective Anti-Parkinson's Disease Agent
Neurol 38:1541-1545, Muenter,M.D.,et al, 1988
Role of Subcutaneous Apomorphine in Parkinsonian Voiding Dysfunction
Lancet 2:1451-1453, Christmas,T.J.,et al, 1988
Intraventricular Bethanechol Infusion for Alzheimer's Disease:Double-Blind & Escalating-Dose Trials
Neurol 38:219-222, 307-3081988., Penn,R.D.,et al, 1988
International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease
Arch Neurol 45:204-208, Kurlan,R., 1988
Subcutaneous Apomorphine in Parkinsonian On-Off Oscillations
Lancet 1:403-406, Stibe,C.M.H.,et al, 1988
Pharmacotherapy for Aphasia
Neurol 38:877-879, Albert,M.L.,et al, 1988
Cerebral Infarction Due to Moyamoya Disease in Young Adults
Stroke 19:826-833, Bruno,A.,et al, 1988
A Double-Blind Randomized Crossover Trial of Bromocriptine & Placebo in Restless Legs Syndrome
Ann Neurol 24:455-458, Walters,A.S.,et al, 1988
The Incidence of Pseudotumor Cerebri, Population Studies in Iowa and Louisiana
Arch Neurol 45:875-877, Durcan,F.J.,et al, 1988
Delirium Tremens, Update on an Old Disorder
Postgrad Med 82:117-122, Cushman,P., 1987
Pleuropulmonary & Retroperitoneal Fibrosis Associated with Bromocriptine Treatment
JNNP 50:1706-1707, Ward,C.D.,et al, 1987
Traveler's Amnesia, Transient Global Amnesia Secondary to Triazolam
JAMA 258:945-946, Morris,H.H.&Estes,M.L., 1987
Relationship of Migraine Headache & Stroke to Oral Contraceptive Use
J Repro Med 31:1082-1088, Benson,M.D.&Rebar,R.W., 1987
Treatment of Gilles de la Tourette's Syndrome:Experience in a Predominantly Adult Population
Neurol 37:1828-1833, Mesulam,M.M.&Peterson,R.C., 1987
Adverse Drug Reactions Associated with Global Cognitive Impairment in Elderly Persons
Ann Int Med 107:169-173, Larson,E.B.,et al, 1987
Giant Invasive Prolactinomas
Am J Med 83:995-1002, Murphy,F.Y.,et al, 1987
Early Combination of Bromocriptine & Levodopa in the Treatment of Parkinson's Disease:A 5-Year Follow-up
Neurol 37:826-828, Rinne,U.K., 1987
Bromocriptine Induced Impotence in Parkinson's Disease
BMJ 295:367-368, Cleves,L., 1987
Extracranial Vertebral Artery Dissections:A Review of 13 Cases
Stroke 18:1037-1047, Mas,J.,et al, 1987
Low-Dose Bromocriptine Therapy in Parkinson's Disease:Double-Blind, Placebo-Controlled Study
Neurol 36:291-293, Staal-Schreinemachers,A.L.,et al, 1986
Use of Oral Contraceptives by Women with Epilepsy
JAMA 256:238-240, Mattson,R.H.,et al, 1986
Optimizing Drug Treatment of Alcohol Withdrawal
Am J Med 81:901-904, Rosenbloom,A.J., 1986
Clobazam for Refractory Focal Epilepsy, A Controlled Trial
Arch Neurol 43:824-826, Schmidt,D.,et al, 1986
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Prolactinomas
Editorial, BMJ 290:182-1841985., Grossman,A.,et al, 1985
Low Dosages of Bromocriptine Added to Levodopa in Parkinson's Disease
Neurol 35:199-206, Maier,M.M.,et al, 1985
Long-Term Study of Pergolide in Parkinson's Disease
Neurol 35:296-299, Jankovic,J., 1985
Placebo-Controlled Study of Mesulergine in Parkinson's Disease
Neurol 35:161-165, Jankovic,J.,et al, 1985
Hyperthermia after Discontinuance of Levodopa & Bromocriptine Therapy:Impaired Dopamine Receptors a Possible Cause
Neurol 35:258-261, Figa-Talamanca,L.,et al, 1985
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
NEJM 313:656-659, Liuzzi,A.,et al, 1985
Cerebrospinal Fluid Rhinorrhea During Treatment with Bromocriptine for Prolactinoma
Neurol 35:1193-1195, Kok,J.G.,et al, 1985
Low-Dose Bromocriptine Therapy in Parkinson's Disease
Arch Neurol 42:586-588, Pfeiffer,R.F.,et al, 1985
Mesulergin (CU32-085) in the Treatment of Parkinson's Disease
Ann Neurol 17:334-336, Pfeiffer,R.F.,et al, 1985
Neuroleptic Malignant Syndrome
NEJM 313:163-166, Guze,B.H.,et al, 1985
Clonidine in the Treatment of"Restless Leg"Syndrome
NEJM 313:1228-1229, Handwerker,J.V.&Palmer,R.F., 1985
Short- & Long-Term Treatment of Tourette's Syndrome with Clonidine:A Clinical Perspective
Neurol 35:343-351, Leckman,J.F.,et al, 1985
Psychotic Reactions During Treatment of Pituitary Tumours with Dopamine Agonists
BMJ 289:1101-1103, Turner,T.H.,et al, 1984
Effect of Dopamine Agonist Withdrawal After Long-Term Therapy in Prolactinomas
Lancet 2:187-192, Johnston,D.G.,et al, 1984
Pergolide in the Treatment of Parkinson's Disease
Neurol 34:983-986, Mear,J.,et al, 1984
Pseudotumor Cerebri & Pregnancy
Neurol 34:721-729, Digre,K.B.,et al, 1984
Rapid Size Reduction of Giant Prolactinoma Following Medical Treatment
J Comput Assist Tomogr 8:131-133, Perani,D.,et al, 1984
Cerebrospinal Fluid Rhinorrhea Caused by Bromocriptine Therapy of Prolactinoma
Neurol 34:111-113, Holness,R.O.,et al, 1984
Treatment of Prolactinomas with Megavoltage Radiotherapy
BMJ 288:1105-1109, Grossman,A.,et al, 1984
Neuroleptic Malignant Syndrome
Lancet 1:545-546, Smego,R.A.,et al, 1984
Clonidine Treatment in Paroxysmal Localized Hyperhidrosis
Arch Neurol 41:1210-1211, Kuritzky,A.,et al, 1984
Oral Contraceptives & Stroke:Findings in a Large Prospective Study
BMJ 289:530-531, Vessey,M.P.,et al, 1984